Abstract
Purpose: The aim of the study is to compare the tumor-specific targeting, pharmacokinetics, and biodistribution of 64Cu- DOTA-HB22.7 when administered to xenograft-bearing mice intravenously (IV), intraperitoneally (IP), and subcutaneously (SQ). Procedures: Mice bearing human non-Hodgkin's lymphoma (NHL) xenografts were injected IV, IP, or SQ with 64Cu-DOTA-HB22.7. Xenograft targeting was evaluated by micro positron emission tomography (microPET) and confirmed by organ biodistribution studies. Blood measurements of 64Cu were performed to determine the pharmacokinetics and clearance of 64Cu-DOTA-HB22.7. Results: 64Cu-DOTA-HB22.7 demonstrated equivalent tumor targeting within 24-48 h, regardless of the route of administration. Organ biodistribution confirmed tumor-specific targeting. Blood pharmacokinetics demonstrated that 64Cu-DOTA-HB22.7 accessed the bloodstream after IP and SQ administration to a similar degree as IV administration, albeit at a slower rate. Conclusions: These findings establish 64Cu-DOTA-HB22.7 as a potential radioimmunotherapeutic and/or NHL-specific imaging agent. These findings provide evidence that IP and SQ administration can achieve results equivalent to IV administration and may lead to more efficient, reproducible treatment plans for antibody-based therapeutics.
Original language | English (US) |
---|---|
Pages (from-to) | 79-87 |
Number of pages | 9 |
Journal | Molecular Imaging and Biology |
Volume | 11 |
Issue number | 2 |
DOIs | |
State | Published - 2009 |
Keywords
- Cu
- CD22
- HB22.7
- Non-Hodgkin's lymphoma
- PET
ASJC Scopus subject areas
- Cancer Research
- Oncology
- Radiology Nuclear Medicine and imaging